Vyome Holdings, Inc annual report, FY2018

Filing and reporting period

Important issuer mismatch: The request identifies Vyome Holdings, Inc., but the supplied filing is Obalon Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2018. This summary reflects the supplied Obalon filing, not a Vyome filing. The filing reports annual results and unaudited quarterly data, including the quarter ended December 31, 2018.

Business context

Obalon develops and sells the FDA-approved Obalon Balloon System, a swallowable, gas-filled intragastric balloon for weight loss. Sales are primarily U.S. self-pay and non-reimbursed. The company was commercializing its earlier balloon system and planned initial U.S. shipments of its Navigation System and Touch Inflation Dispenser in the first quarter of 2019.

Financial performance and liquidity

For Q4 2018, revenue was $2.0 million, gross profit $0.5 million, operating loss $8.7 million, and net loss $8.8 million. Q4 2017 comparatives were revenue of $3.7 million, gross profit of $2.0 million, operating loss of $9.9 million, and net loss of $10.1 million.

At December 31, 2018, cash and cash equivalents were $21.2 million and short-term investments $2.5 million, totaling $23.7 million. Working capital was $11.4 million; total assets were $30.4 million; and stockholders’ equity was $13.1 million. The balance sheet showed $9.9 million of loan debt, classified as current. The company subsequently drew the remaining $10.0 million loan tranche in Q1 2019, bringing principal and interest outstanding to approximately $20.0 million as of February 2019. The loan is secured by substantially all assets, carries a variable rate (7.0% at year-end 2018), and has a minimum bank-account balance covenant tied to outstanding debt.

Changes and management outlook

• Annual revenue fell 8% year over year. Management attributed the decrease principally to lower U.S. revenue and lower worldwide average selling prices, partly offset by higher Middle East distributor sales. International sales were 48.4% of revenue in 2018 versus 16.7% in 2017.
• Gross margin declined from 51.3% to 40.4%, reflecting sales mix, lower transfer prices to the Middle East distributor, and inventory reserves related to the new system launch.
• Management reported that total balloon units sold increased, but U.S. units declined. It does not expect sales to a significant U.S. customer that contributed $1.1 million of 2018 sales to recur.
• The company completed final shipments to its Middle East distributor in Q1 2019 and does not expect international revenue in 2019. It plans to phase out the x-ray-based system and transition customers to Navigation; management cautioned that inability to transition physicians could reduce sales.
• No formal numerical revenue or earnings guidance is provided. Management expected continuing losses and substantial spending on U.S. commercialization, market development, manufacturing capacity, research and development, and clinical studies.
• The company and auditor disclosed substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements. Management planned to seek financing, including through a $10 million at-the-market facility and a $20 million Lincoln Park purchase agreement, but access and proceeds are not assured and could dilute shareholders.

Risks, contingencies, and unusual items

• Obalon is a single-product company operating in a small, immature market, with a history of losses and no demonstrated path to profitability. Annual net losses increased in 2018.
• Manufacturing scale-up, product yields, and dependence on single-source suppliers could constrain supply or raise costs. The Navigation console was expected to be sold near cost, and management anticipated lower initial margins for the new system.
• Products require FDA oversight and post-approval studies. The company reported one serious adverse device event in its pivotal trial and two serious events in its first-year commercial registry; it also disclosed reports of serious injuries associated with product use. Broader FDA warnings concerning liquid-filled balloons could affect perceptions of the entire category.
• A shareholder class action alleging misleading statements and securities-law violations remained pending; the company said it believed the claims were without merit and had moved to dismiss. A hearing was scheduled for April 11, 2019. The company also had indemnification obligations to IPO underwriters in the litigation.
• A purported whistleblower allegation concerning Q4 2017 revenue recognition led to an audit committee investigation and termination of a planned stock offering in January 2018. The company said the allegations were without merit; related investigation and litigation costs contributed to higher 2018 SG&A.
• Other notable risks include self-pay demand sensitivity, competition, product liability, regulatory compliance, dilution from future financings, and loan covenant default or acceleration if required cash balances are not maintained.

Key facts investors should verify

• Confirm the issuer identity: the supplied document is Obalon Therapeutics, Inc., not Vyome Holdings, Inc.
• Review the going-concern disclosure, available cash and investments, financing availability, and subsequent $10 million loan draw.
• Track whether the Navigation product launch and physician transition proceed, and whether U.S. demand offsets the loss of expected international revenue.
• Assess gross-margin trends, manufacturing costs, inventory reserves, and reliance on the Middle East distributor and other concentrated customers.
• Check developments in the shareholder litigation, post-approval studies, and any new product-safety or regulatory disclosures.
• Consider potential share dilution and the restrictions and availability under the ATM and Lincoln Park financing arrangements.